About Us
ACADIA Pharmaceuticals is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. More »
News
May 15, 2013
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
May 14, 2013
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
Product Candidates
We have a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. More »
Company Information
 |
Learn More: Pimavanserin Phase III Program for Parkinson's Disease Psychosis » |
 |
Investor Webcasts » |  |
Email Updates » |